Physician profile
Christopher James Capps
NPI 1437629136
$7,567.38
in general payments reported to CMS, 2019-2025
38 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $718 · 2022: $1,783 · 2023: $1,651 · 2024: $1,932 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,828 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,828.34 |
| Education | $238.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,365.84 | 2022-2025 | Cardiomems, Diamondback Peripheral, Jeti Peripheral Catheter |
| Novartis Pharmaceuticals Corporation | $1,034.34 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $980.48 | 2021-2025 | Brilinta, Farxiga |
| Amgen INC. | $701.68 | 2021-2025 | Repatha, Repatha |
| Heartflow, INC. | $517.64 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $411.22 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.13 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $365.63 | 2021-2024 | Xarelto |
| Astellas Pharma US INC | $206.27 | 2022 | |
| Esperion Therapeutics, INC. | $155.27 | 2021-2023 | Nexletol |
| Boston Scientific Corporation | $153.21 | 2022-2025 | Watchman Flx, Ekosonic |
| Pfizer INC. | $150.28 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $138.24 | 2023-2025 | Verquvo, Winrevair |
| E.R. Squibb & Sons, L.L.C. | $135.10 | 2022-2025 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $98.39 | 2023-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $69.42 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $67.59 | 2022-2025 | Evkeeza |
| Kestra Medical Technology Services, INC. | $67.22 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $63.39 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $51.08 | 2023 | Onpattro |
| Chiesi USA, INC. | $41.47 | 2023-2024 | Kengreal, Cleviprex |
| Cardiovascular Systems INC. | $39.44 | 2021 | |
| Ethicon US, LLC | $35.30 | 2025 | Vistaseal, Stratafix, Dermabond |
| Lexicon Pharmaceuticals, INC. | $31.38 | 2023-2024 | Inpefa |
| Imperative Care, INC | $25.49 | 2025 | Symphony Catheter |
| Abiomed | $25.14 | 2025 | |
| Edwards Lifesciences Corporation | $24.74 | 2022 | |
| Daiichi Sankyo INC. | $23.94 | 2023 | Injectafer |
| Teleflex LLC | $23.07 | 2025 | Guideliner |
| Recor Medical INC | $23.05 | 2024 | Paradise Renal Denervation System |
| Cardiva Medical, INC. | $21.34 | 2024 | Cardiva Vascade 5f Vcs |
| Glaxosmithkline, LLC. | $21.16 | 2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $20.75 | 2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.11 | 2023 | Lifevest |
| Medtronic, INC. | $17.87 | 2023 | Linq II |
| Lantheus Medical Imaging, INC. | $15.46 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $14.01 | 2023 | Arcalyst |
| Cvrx, INC. | $13.24 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Capps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.